Medicines Transparency Alliance20/04/23 1

MeTA Ghana

Augustina Koduah (Mrs)Country Coordinator

Medicines Transparency Alliance20/04/23 2

Multi-stakeholder process [What were the major milestone in the multi-stakeholder

process?] Inaugural Meeting of Governing Council by Deputy Minister in September 2008

Official Launch in November 2008

First National forum in December 2009

CSO & Media Orientation in April 2009

Quarterly Governing Council Meetings to date

Independent monitoring of medicines quality through routine testing with FDB & monitoring access to medicines using NHIS data based on agreed indicators with NHIA established

Participated in major MeTA led International activities [MIAG & Jordan Training]

Launch and Sensitization of Ghana MeTA CSO Group community targeted communication activities in April 2010

Medicines Transparency Alliance20/04/23 3

Picture & Text example

Multi-stakeholder analysis workshop carried out in June 2010

National Multi-stakeholder Technical discussion forum on data disclosure in June 2010

Medicines Transparency Alliance

Major achievements and successes

[What where the main achievements and successes of MeTA in your country? ]

Active Multi-stakeholder Council made up of excellent spread of relevant stakeholders with sub committees (Administration, Advocacy & Technical) & a strong interest to move forward towards regular dialogue on medicines issues

Independent Secretariat & Functional Website www.metaghana.org

Facilitated an active independent civil society capacity to lead consumer advocacy campaign to support disclosure and accountability on access to medicines

Baseline Pharmaceutical disclosure survey & sector scan studies completed

Good collaboration established with NHIA to use data to monitor access to medicines based on agreed indicators with promising public health benefits

Case studies shared with other MeTA countries through international meetings and country exchange visits

20/04/23 4

Medicines Transparency Alliance20/04/23 5

Major Achievement

Results of Routine Minilab Quality Assurance Test led to necessary regulatory interventions

Medicines Transparency Alliance

Overall challenges

[What have been the main challenges during the MeTA pilot phase? ]

Initial unclear Standard Operating Procedures

Latent mutual suspicion between the state and private sector;

Nervousness of some stakeholders about change;

MeTA assumes that enforcement mechanisms exist across the medicines manufacture, import, procurement and distribution systems, but historically enforcement of regulations is weak;

Slow and Bureaucratic Decision Making process

Maintaining momentum of stakeholders over time. (Diminishing returns)

Working together to build trust & understanding between different stakeholders is difficult

Timeliness and sustainability of financing beyond the pilot phase.

20/04/23 6

Medicines Transparency Alliance

Lessons Learned

[What are the main lessons from MeTA in your country? ]

Players in the pharmaceutical sector have varying interest and power

Multi-stakeholder groups in the pharmaceutical sector have a better understanding of each other through transparent and systematic engagement

Potential to make a positive impact in medicines access through transparent multi-stakeholder and systematic data sharing and disclosure works.

Providing Ghanaian leadership on medicines transparency disclosure and dissemination of information to eliminate the risk of counterfeit and substandard medication as well as pricing in the supply chain

20/04/23 7

Medicines Transparency Alliance20/04/23 8

Thank you

Name of presenter : Augustina Koduah (Mrs) Email: appidanq@yahoo.com

Mobile number: +233 20 8769228

Skype:

Website: